Artikel
Antibodies against MYC-associated Zink Finger Protein: A biomarker for early atherosclerosis?
Suche in Medline nach
Autoren
-
Diana Ernst
- Medizinische Hochschule Hannover, Klinik für Immunologie und Rheumatologie, Hannover
-
Niklas Baerlecken
- Medizinische Hochschule Hannover, Klinik für Immunologie und Rheumatologie, Hannover
-
Desiree Weiberg
- Medizinische Hochschule Hannover, Hannover
-
Thorsten Derlin
- Medizinische Hochschule Hannover, Klinik für Nuklearmedizin - Zentrum Radiologie, Hannover
-
Wolfgang Schlumberger
- EUROIMMUN Medizinische Labordiagnostika AG, Lübeck
-
Reinhold E. Schmidt
- Medizinische Hochschule Hannover, Klinik für Immunologie und Rheumatologie, Hannover
-
Torsten Witte
- Medizinische Hochschule Hannover, Klinik für Immunologie und Rheumatologie, Hannover
| Veröffentlicht: | 29. August 2016 |
|---|
Gliederung
Text
Background: Atherosclerosis is a chronic inflammatory disorder of the vessel wall that may lead to atherothrombotic complications including myocardial infarction and stroke. Although numerous risk factors are known, the availability of biomarkers is limited. An autoimmune component in atherosclerosis has been suggested. We have identified antibodies against MYC-associated zinc finger protein (MAZ-Ab) using protein array technology in patients with acute myocardial infarction. Aim of the study was to characterize if MAZ-Ab correlates with asymptomatic atherosclerotic disease.
Methods: A priori enrollment of patients attending for unrelated CT scans was performed. Scans were assessed by blinded radiologists for atherosclerosis at 3 sites: coronary vessels, aorta and peripheral vessels. A new ELISA test specific for anti-MAZ antibodies was developed and used to assess patients with and without atherosclerosis to establish its utility in identifying asymptomatic atherosclerosis, with anti-MAZ-Ab cut-offs being defined with aid of control sera.
Results: In total 216 patients were enrolled (32% female) with a median age of 60.9 years (IQR 48.95-65.95). MAZ-Ab values did not show any correlation to age (p=0.878) or gender (female p=0.612 and male p=0.954). Atherosclerotic plaques at any sites were seen in CT in 92 (43%) patients. In these patients MAZ-Ab were significantly higher than in the group without any atherosclerotic plaques in CT (p=0.011, median MAZ-Ab OD 0.39 vs. 0.58).
Of the 92 CT positive patients 30 (33%) had single site disease, 33 (36%) had two sites disease and 29 (32%) had plaques detected at all three sites. The number of sites involved correlated with increasing MAZ-Ab (p=0.02). There was no significant difference in MAZ-Ab values between the sites of atherosclerosis, only a trend towards peripheral vessels (p=0.07).Anti-MAZ-ab correlated significantly with sub-clinical atherosclerotic disease (p=0.0001).
Conclusion: This preliminary data supports an autoimmune component in atherosclerosis. MAZ-ab may be a biomarker for subclinical atherosclerosis.Further research is warranted to evaluate its diagnostic use.
